home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor
Post navigation
Previous Post
Previous
Arvinas, Inc. Announces Proposed Offering of Common Stock
Next Post
Next
Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights